Highlights

  • HCWB shares declined 7.54% to USD 0.60 following the offering announcement.
  • The company priced 2,477,292 units at USD 0.6055 per unit.
  • Gross proceeds of about USD 1.5 million are earmarked for clinical development.

Shares of HCW Biologics Inc. (NASDAQ:HCWB) closed at USD 0.60 on February 18, down USD 0.049 or 7.54% for the session. The decline followed the company’s announcement of a USD 1.5 million follow-on offering priced at-the-market under Nasdaq rules. The pricing of the new units at USD 0.6055, close to the prevailing market level, appeared to weigh on investor sentiment during the trading session.

Details of the Follow-On Offering
The company announced the pricing of 2,477,292 units at a purchase price of USD 0.6055 per unit. Each unit consists of one share of common stock, or a pre-funded warrant in lieu thereof, along with one warrant to purchase one share of common stock. The warrants will carry an exercise price of USD 0.6055 per share, become exercisable upon shareholder approval, and expire five years after such approval.

The securities are being offered under an effective Form S-1 registration statement declared effective by the U.S. Securities and Exchange Commission on February 17, 2026. The offering is expected to close on or about February 19, 2026, subject to customary closing conditions. Maxim Group LLC is acting as the sole placement agent.

Use of Proceeds and Warrant Adjustment
Gross proceeds from the offering are expected to total approximately USD 1.5 million before deducting placement agent fees and other expenses. The company stated that net proceeds are intended to fund preclinical and clinical development activities, including clinical trials for HCW9302, as well as general corporate purposes.

In a related move, the company entered into a privately negotiated agreement with the holder of certain existing warrants covering up to 3,020,410 shares. The exercise price of these warrants is proposed to be reduced from USD 2.41 per share to USD 0.6055 per share, subject to shareholder approval. This adjustment aligns the warrant pricing with the newly issued units.

With its shares declining following the USD 1.5 million at-the-market offering, HCW Biologics Inc. is navigating a capital-raising phase tied to ongoing clinical and preclinical programs. Investors are monitoring the closing of the offering, shareholder approvals related to warrants, and the progress of its lead candidate HCW9302 as the company advances its development pipeline.

FAQs

Q1. Why did HCW Biologics’ stock decline on February 18, 2026?
HCW Biologics’ stock fell 7.54% to USD 0.60 after the company announced a USD 1.5 million follow-on offering priced at-the-market, which may have influenced short-term investor sentiment.

Q2. What are the key terms of HCW Biologics’ latest offering?
The company priced 2,477,292 units at USD 0.6055 per unit, with each unit including one common share or pre-funded warrant and one warrant exercisable at USD 0.6055 per share.

Q3. How will HCW Biologics use the proceeds from the offering?
The expected net proceeds are intended to fund preclinical and clinical development activities, including trials for HCW9302, along with supporting general corporate purposes.